Uniqures new COO to oversee GMP
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
Hansas immunomodulatory enzyme does the job
/in News/by Thomas GabrielczykSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
J&J intensifies vaccine endeavour with Bavarian Nordic
/in News/by Thomas GabrielczykJohnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
/in News/by Thomas GabrielczykUKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]
Ablynx adds Sanofi to its list of pharma partners
/in News/by Thomas GabrielczykBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners […]
Seventure debuts in Japan with microbiome investment
/in News/by Thomas GabrielczykVenture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment […]